Mannkind (MNKD) Return on Capital Employed (2011 - 2026)
Mannkind (MNKD) posted quarterly Return on Capital Employed of 2.34% for Q1 2026, down 2498.0% year-over-year from 0.1% in Q1 2025, and down 71.49% quarter-over-quarter from 8.21% in Q4 2025.
Mannkind (MNKD) Return on Capital Employed (2011 - 2026) Analysis & Trends
Mannkind (MNKD) has reported Return on Capital Employed for 16 consecutive years, with 2.34% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 2498.0% year-over-year to 2.34%; the TTM figure through Mar 2026 stood at 2.34% (down 2498.0% YoY), while the FY2025 annual figure was 9.19%, down 1139.0% from the prior year.
- Return on Capital Employed eased to 2.34% in Q1 2026 per MNKD's latest filing, from 8.21% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 27.32% in Q1 2025 and bottomed at 32.7% in Q3 2022.
- Historically, Return on Capital Employed has averaged 0.95% across 5 years, with a median of 2.96% in 2023.
- Annual changes were most pronounced in 2023 — Return on Capital Employed jumped 3116 bps — and 2026, when it tumbled 2498 bps.
- Mannkind's Return on Capital Employed stood at 28.21% in 2022, then jumped by 110 bps to 2.96% in 2023, then surged by 607 bps to 20.91% in 2024, then tumbled by 61 bps to 8.21% in 2025, then sank by 71 bps to 2.34% in 2026.
- Business Quant data shows MNKD's Return on Capital Employed at 2.34% in Q1 2026, 8.21% in Q4 2025, and 21.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn | 1.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.54% |
| Mar 31, 2026 | 2.34% |
| Dec 31, 2025 | 8.21% |
| Sep 30, 2025 | 21.21% |
| Jun 30, 2025 | 22.35% |
| Mar 31, 2025 | 27.32% |
| Dec 31, 2024 | 20.91% |
| Sep 30, 2024 | 14.13% |
| Jun 30, 2024 | 12.11% |
| Mar 31, 2024 | 8.30% |
| Dec 31, 2023 | 2.96% |
| Sep 30, 2023 | -5.43% |
| Jun 30, 2023 | -12.78% |
| Mar 31, 2023 | -22.74% |
| Dec 31, 2022 | -28.21% |
| Sep 30, 2022 | -32.70% |
| Jun 30, 2022 | -30.43% |
| Mar 31, 2022 | -23.77% |
| Dec 31, 2021 | -20.33% |
| Sep 30, 2021 | -23.94% |